Professor, Nanomedicine, Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research
Deakin University, Australia
Dr. Jagat R Kanwar is the Professor in Nanomedicine and Head of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (N-LIMBR) at School of Medicine (SoM), Molecular and Medical Research (MMR) Strategic Research Centre, Faculty of Health, Deakin University. He has an international reputation and expertise in investigating fundamental and applied molecular signalling aspects of pathogenesis of cancer, chronic inflammation and neurodegenerative diseases, thereby, leading to the development of treatment strategies from bench to bedside. He has an international reputation and expertise in investigating fundamental and applied molecular signalling aspects of pathogenesis of cancer, chronic inflammation and neurodegenerative diseases, thereby, leading to the development of treatment strategies. He has more than 120 publications in high impact factor and peer reviewed international journals, 17 book chapters and 2 edited books. Prof Kanwar’s research has generated several patents/PCTs with more than five licensed patents for commercialization to BioPharma industry. His group is currently working on drug discovery and nanomedicine for oral and systemic drug delivery of a range of biomacromolecules (proteins/peptides, siRNAs and aptamers) for targeting survivin, HIF-1α and other apoptotic and inflammatory cell signalling molecules in cancer, chronic inflammation and neurodegenerative disorders. He is an active member and delegate in various professional bodies including American Society of Nanomedicine, Australian Nanotechnology network, and a regular grant reviewer for national, international and corporate funding agencies.
His research interest are in Cancer and chronic inflammatory diseases targeted Nanomedicine based drug delivery,Locked nucleic acid (LNA) modified aptamers conjugation with drugs and recombinant proteins or peptides to target cancer and chronic inflammatory diseases,LNA modified aptamers conjugation with nanoparticles for targeted real-time delivery and imaging for cancers and chronic inflammatory diseases,development of novel formulations to clear haze/scarring and inflammation in eye animal model ,development of nano-formulations to induce myofibroblast cell specific apoptosis to clear haze/scarring and inflammation, simultaneously in eye animal model ,siRNA, miRNA anti-sense targeted gene nanomedicine based technology to target cancer and inflammation,drug discovery with anticancer targets for cancer cell survival, death, arrest, and repair,development of recombinant proteins and searching new immunomodulatory and anti-inflammatory bioactives, proteins and peptides for cancer and neuroprotection,development of complementary alternative medicine from the milk derived proteins including metal binding protein (Lactoferrin), and herbal preparation derived active components with a special focus on the treatment of colon and breast cancers,development of oral and intravenous administration of nanocarriers to overcome the challenging concept of drug resistance in various cancers and development of new generation safe, biodegradable, less toxic, disease targeted natural contrast materials for imaging.